The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021
Open accessAbstract
Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after a typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3).In the United States, the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is currently authorized for use in children and adolescents aged 5-15 years under an Emergency Use Authorization and is fully licensed by the Food and Drug Administration for persons aged ≥16 years (4).Prelicensure randomized trials in persons aged ≥5 years documented high vaccine efficacy and immunogenicity (5), § and real-world studies in persons aged 12-18 years demonstrated high vaccine effectiveness (VE) against severe COVID-19 (6).Recent evidence suggests that COVID-19 vaccination is associated with lower MIS-C incidence among adolescents (7); however, VE of the 2-dose Pfizer-BioNTech regimen against MIS-C has not been evaluated.The effectiveness of 2 doses of Pfizer-BioNTech vaccine received ≥28 days before hospital admission in preventing MIS-C was assessed using a test-negative case-control design ¶ among hospitalized patients aged 12-18 years at 24 pediatric hospitals in 20 states** during July 1-December 9, 2021, the period when most MIS-C patients could be temporally linked to * These authors contributed equally to this report.† These senior authors contributed equally to this report.§ https://www.fda.gov/emergency-preparedness-and-response/coronavirus- disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine ¶ In this context, the test-negative case-control design was used to compare the odds of previous Pfizer-BioNTech vaccine receipt among inpatients without evidence of SARS-CoV-2 infection with case-patients hospitalized for MIS-C.These control patients included those with respiratory virus infection who received a negative test result for SARS-CoV-2 infection (test-negative) or patients without symptoms compatible with COVID-19 (syndrome-negative), including fever, cough, shortness of breath, loss of taste, loss of smell, gastrointestinal symptoms, use of respiratory support for the acute illness, or new pulmonary findings on chest imaging consistent with pneumonia.** This investigation included patients enrolled from 24 pediatric hospitals in 20 states: Alabama, Arkansas, California, Colorado, Georgia, Illinois, Indiana, Louisiana, Massachusetts, Michigan, Mississippi, Missouri, Nebraska, New Jersey, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, and Texas.Abbreviations: MIS-C = multisystem inflammatory syndrome in children; RT-PCR = reverse transcription-polymerase chain reaction; SVI = social vulnerability index.* Patients included vaccinated and unvaccinated persons aged 12-18 years enrolled from 24 pediatric hospitals in 20 states.Northeast: Boston Children's Hospital (Massachusetts), Children's Hospital of Philadelphia (Pennsylvania), and Saint Barnabas Medical Center (New Jersey); Midwest: Akron Children's Hospital (Ohio), Children's Hospital and Medical Center: Nebraska (Nebraska), Children's Hospital of Michigan (Michigan), Children's Mercy Kansas City (Missouri), Cincinnati Children's Hospital Medical Center (Ohio), Lurie Children's Hospital of Chicago (Illinois), Mayo Clinic (Minnesota), Nationwide Children's Hospital (Ohio), and Riley Children's Hospital (Indiana); South: Arkansas Children's Hospital (Arkansas), Children's of Alabama (Alabama), Children's Healthcare of Atlanta (Georgia), Children's Hospital of New Orleans (Louisiana), Medical University of South Carolina Children's Health (South Carolina), Monroe Carell Jr. Children's Hospital at Vanderbilt (Tennessee)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Feldstein, L. R., Rose, E. B., Horwitz, S. M., Collins, J. P., Newhams, M. M., Son, M. B. F., Newburger, J. W., Kleinman, L. C., Heidemann, S. M., Martin, A. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021680 · Cited by 2,643
Self-citationMultisystem Inflammatory Syndrome in Children in New York State
Dufort, E. M., Koumans, E. H., Chow, E. J., Rosenthal, E. M., Muse, A., Rowlands, J., Barranco, M. A., Maxted, A. M., Rosenberg, E. S., Easton, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021756 · Cited by 1,350
Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents
Frenck, R. W., Klein, N. P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J. L., Walter, E. B., Senders, S., Bailey, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107456 · Cited by 889
Belay, E. D., Abrams, J., Oster, M. E., Giovanni, J., Pierce, T., Meng, L., Prezzato, E., Balachandran, N., Openshaw, J. J., Rosen, H. E., et al. (2021) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2021.0630 · Cited by 279
Self-citationTenforde, M. W., Patel, M. M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A. E., Gaglani, M., McNeal, T., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab687 · Cited by 249
Self-citationLevy, M., Recher, M., Hubert, H., Javouhey, E., Fléchelles, O., Leteurtre, S., & Angoulvant, F. (2022) · JAMA · doi:10.1001/jama.2021.23262 · Cited by 178
Olson, S. M., Newhams, M. M., Halasa, N., Price, A. M., Boom, J. A., Sahni, L. C., Irby, K., Walker, T. C., Schwartz, S. P., Pannaraj, P. S., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7042e1 · Cited by 101
Self-citation
Cited by
Pratama, N. R., Wafa, I. A., Budi, D. S., Sutanto, H., Asmarawati, T. P., Barlian Effendi, G., & Wungu, C. D. K. (2022) · Vaccines · doi:10.3390/vaccines10122180 · Cited by 30
“, 2022(39) Retrosp ective Cohort Qatar 2,239,193 No restriction Viral genome sequencing 21 (11-38) 22 (12-38) BNT162b2, mRNA-1273 Symptomatic infection and severe infection 1-HR”
Background
Metadata
- Authors
- Zambrano, L. D., Newhams, M. M., Olson, S. M., Halasa, N. B., Price, A. M., Boom, J. A., Sahni, L. C., Kamidani, S., Tarquinio, K. M., Maddux, A. B., Heidemann, S. M., Bhumbra, S. S., Bline, K. E., Nofziger, R. A., Hobbs, C. V., Bradford, T. T., Cvijanovich, N. Z., Irby, K., Mack, E. H., Cullimore, M. L., Pannaraj, P. S., Kong, M., Walker, T. C., Gertz, S. J., Michelson, K. N., Cameron, M. A., Chiotos, K., Maamari, M., Schuster, J. E., Orzel, A. O., Patel, M. M., Campbell, A. P., Randolph, A. G., Overcoming COVID-19 Investigators, Overcoming COVID-19 Investigators, Murdock, M., Gaspers, M. G., Typpo, K. V., Kelley, C. P., Sanders, R. C., Yates, M., Smith, C., Crane, K., Lionetti, G., Murcia-Montoya, J., Zinter, M. S., Villarreal-Chico, D., Skura, A. L., Peralta, H., Lockwood, J. M., Port, E., Carson, I. A., Chatani, B. M., Hussaini, L., Baida, N., Coates, B. M., Rowan, C. M., Stumpf, M., Johnston, M. S., Boutselis, B. J., Kucukak, S., Chen, S. R., Weller, E., Berbert, L., He, J., Flori, H. R., Hume, J. R., Bruno, E. R., Goertzen, L. A., Levy, E. R., Behl, S., Drapeau, N. M., Martin, L., Malloch, L., Sanders, C., Patterson, K., Dhanrajani, A., Hill, S. M., Kietzman, A., Rinehart, V. H., Hoody, L. A., Schwartz, S. P., Navas, A. G., Bennett, P. C., Twinem, N. A., Tomcany, M. L., Staat, M. A., Rohlfs, C. C., Wolfe, A., Douglas, R. L., Phengchomphet, K., Bickford, M. M., Wakefield, L. E., Smallcomb, L., Stewart, L. S., Golchha, M., Oates, J. N., & Bowens, C.
- Venue
- MMWR. Morbidity and Mortality Weekly Report
- Published
- 2022-01-14
- Volume
- 71
- Issue
- 2
- Pages
- 52-58
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- OpenAlex
- W4205489649
- Cited by
- 279
- References
- 7
- FWCI
- 57.01
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021. https://app.cochat.ai/papers/10.15585/mmwr.mm7102e1
- The paper
- Zambrano, L. D., Newhams, M. M., Olson, S. M., Halasa, N. B., Price, A. M., Boom, J. A., Sahni, L. C., Kamidani, S., Tarquinio, K. M., Maddux, A. B., Heidemann, S. M., Bhumbra, S. S., Bline, K. E., Nofziger, R. A., Hobbs, C. V., Bradford, T. T., Cvijanovich, N. Z., Irby, K., Mack, E. H., . . . Bowens, C. (2022). Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7102e1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.